Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia
Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2012-09, Vol.96 (3), p.357-363 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 363 |
|---|---|
| container_issue | 3 |
| container_start_page | 357 |
| container_title | International journal of hematology |
| container_volume | 96 |
| creator | Takami, Akiyoshi Ohtake, Shigeki Morishita, Eriko Terasaki, Yasushi Fukushima, Toshihiro Kurokawa, Toshiro Sugimori, Naomi Matano, Sadaya Ohata, Kinya Saito, Chizuru Yamaguchi, Masaki Hosokawa, Kohei Yamazaki, Hirohito Kondo, Yukio Nakao, Shinji |
| description | Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose |
| doi_str_mv | 10.1007/s12185-012-1155-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1040997516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1040997516</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-c47f344890a227445553371eaf68c084b1460e3341ee3821c632be48b25d36653</originalsourceid><addsrcrecordid>eNp1kE2LFDEQhoO4uOPqD_AiARG8tJvKdx9lWT9gwMvuxUuTzlQ7WbuTNulm2X9vhplVEbwkleSpN8VDyCtg74Exc1mAg1UNA94AKNXAE7IBq1UjjJFPyYa1XDXKADsnz0u5YwwMk-YZOefctgKY3ZBvW7cgzVjmFAvSJdEx3Te7VOswuSXE0NMQ6VxLjEuh92HZU7_PKQZP572r3ONpesAxhR0dcf2BU3AvyNngxoIvT_sFuf14fXP1udl-_fTl6sO28VKppa5mEFLaljnOjax3SggD6AZtPbOyB6kZCiEBUVgOXgveo7Q9VzuhtRIX5N0xd87p54pl6aZQPI6ji5jW0gGTrG2NAl3RN_-gd2nNsU5XKdGqtuVaVAqOlM-plIxDN-cqIz9UqDuI747iuyq-O4jvoPa8PiWv_YS73x2Ppivw9gS44t04ZBd9KH84LSqoDkH8yJX6FL9j_nvE__3-C-X6mKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1039599263</pqid></control><display><type>article</type><title>Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Takami, Akiyoshi ; Ohtake, Shigeki ; Morishita, Eriko ; Terasaki, Yasushi ; Fukushima, Toshihiro ; Kurokawa, Toshiro ; Sugimori, Naomi ; Matano, Sadaya ; Ohata, Kinya ; Saito, Chizuru ; Yamaguchi, Masaki ; Hosokawa, Kohei ; Yamazaki, Hirohito ; Kondo, Yukio ; Nakao, Shinji</creator><creatorcontrib>Takami, Akiyoshi ; Ohtake, Shigeki ; Morishita, Eriko ; Terasaki, Yasushi ; Fukushima, Toshihiro ; Kurokawa, Toshiro ; Sugimori, Naomi ; Matano, Sadaya ; Ohata, Kinya ; Saito, Chizuru ; Yamaguchi, Masaki ; Hosokawa, Kohei ; Yamazaki, Hirohito ; Kondo, Yukio ; Nakao, Shinji</creatorcontrib><description>Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300 mg per day) due to intolerance, in comparison to optimal-dose imatinib (≥300 mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan–Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420 days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720 days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-012-1155-1</identifier><identifier>PMID: 22893108</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - administration & dosage ; Benzamides ; Biological and medical sciences ; Child ; Female ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Imatinib Mesylate ; Leukemia, Myeloid, Chronic-Phase - drug therapy ; Leukemia, Myeloid, Chronic-Phase - mortality ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Piperazines - administration & dosage ; Protein Kinase Inhibitors - administration & dosage ; Pyrimidines - administration & dosage ; Retrospective Studies ; Treatment Outcome ; Young Adult</subject><ispartof>International journal of hematology, 2012-09, Vol.96 (3), p.357-363</ispartof><rights>The Japanese Society of Hematology 2012</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-c47f344890a227445553371eaf68c084b1460e3341ee3821c632be48b25d36653</citedby><cites>FETCH-LOGICAL-c455t-c47f344890a227445553371eaf68c084b1460e3341ee3821c632be48b25d36653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-012-1155-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-012-1155-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26389351$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22893108$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takami, Akiyoshi</creatorcontrib><creatorcontrib>Ohtake, Shigeki</creatorcontrib><creatorcontrib>Morishita, Eriko</creatorcontrib><creatorcontrib>Terasaki, Yasushi</creatorcontrib><creatorcontrib>Fukushima, Toshihiro</creatorcontrib><creatorcontrib>Kurokawa, Toshiro</creatorcontrib><creatorcontrib>Sugimori, Naomi</creatorcontrib><creatorcontrib>Matano, Sadaya</creatorcontrib><creatorcontrib>Ohata, Kinya</creatorcontrib><creatorcontrib>Saito, Chizuru</creatorcontrib><creatorcontrib>Yamaguchi, Masaki</creatorcontrib><creatorcontrib>Hosokawa, Kohei</creatorcontrib><creatorcontrib>Yamazaki, Hirohito</creatorcontrib><creatorcontrib>Kondo, Yukio</creatorcontrib><creatorcontrib>Nakao, Shinji</creatorcontrib><title>Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300 mg per day) due to intolerance, in comparison to optimal-dose imatinib (≥300 mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan–Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420 days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720 days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Leukemia, Myeloid, Chronic-Phase - drug therapy</subject><subject>Leukemia, Myeloid, Chronic-Phase - mortality</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Piperazines - administration & dosage</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Pyrimidines - administration & dosage</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE2LFDEQhoO4uOPqD_AiARG8tJvKdx9lWT9gwMvuxUuTzlQ7WbuTNulm2X9vhplVEbwkleSpN8VDyCtg74Exc1mAg1UNA94AKNXAE7IBq1UjjJFPyYa1XDXKADsnz0u5YwwMk-YZOefctgKY3ZBvW7cgzVjmFAvSJdEx3Te7VOswuSXE0NMQ6VxLjEuh92HZU7_PKQZP572r3ONpesAxhR0dcf2BU3AvyNngxoIvT_sFuf14fXP1udl-_fTl6sO28VKppa5mEFLaljnOjax3SggD6AZtPbOyB6kZCiEBUVgOXgveo7Q9VzuhtRIX5N0xd87p54pl6aZQPI6ji5jW0gGTrG2NAl3RN_-gd2nNsU5XKdGqtuVaVAqOlM-plIxDN-cqIz9UqDuI747iuyq-O4jvoPa8PiWv_YS73x2Ppivw9gS44t04ZBd9KH84LSqoDkH8yJX6FL9j_nvE__3-C-X6mKw</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Takami, Akiyoshi</creator><creator>Ohtake, Shigeki</creator><creator>Morishita, Eriko</creator><creator>Terasaki, Yasushi</creator><creator>Fukushima, Toshihiro</creator><creator>Kurokawa, Toshiro</creator><creator>Sugimori, Naomi</creator><creator>Matano, Sadaya</creator><creator>Ohata, Kinya</creator><creator>Saito, Chizuru</creator><creator>Yamaguchi, Masaki</creator><creator>Hosokawa, Kohei</creator><creator>Yamazaki, Hirohito</creator><creator>Kondo, Yukio</creator><creator>Nakao, Shinji</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120901</creationdate><title>Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia</title><author>Takami, Akiyoshi ; Ohtake, Shigeki ; Morishita, Eriko ; Terasaki, Yasushi ; Fukushima, Toshihiro ; Kurokawa, Toshiro ; Sugimori, Naomi ; Matano, Sadaya ; Ohata, Kinya ; Saito, Chizuru ; Yamaguchi, Masaki ; Hosokawa, Kohei ; Yamazaki, Hirohito ; Kondo, Yukio ; Nakao, Shinji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-c47f344890a227445553371eaf68c084b1460e3341ee3821c632be48b25d36653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Leukemia, Myeloid, Chronic-Phase - drug therapy</topic><topic>Leukemia, Myeloid, Chronic-Phase - mortality</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Piperazines - administration & dosage</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Pyrimidines - administration & dosage</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takami, Akiyoshi</creatorcontrib><creatorcontrib>Ohtake, Shigeki</creatorcontrib><creatorcontrib>Morishita, Eriko</creatorcontrib><creatorcontrib>Terasaki, Yasushi</creatorcontrib><creatorcontrib>Fukushima, Toshihiro</creatorcontrib><creatorcontrib>Kurokawa, Toshiro</creatorcontrib><creatorcontrib>Sugimori, Naomi</creatorcontrib><creatorcontrib>Matano, Sadaya</creatorcontrib><creatorcontrib>Ohata, Kinya</creatorcontrib><creatorcontrib>Saito, Chizuru</creatorcontrib><creatorcontrib>Yamaguchi, Masaki</creatorcontrib><creatorcontrib>Hosokawa, Kohei</creatorcontrib><creatorcontrib>Yamazaki, Hirohito</creatorcontrib><creatorcontrib>Kondo, Yukio</creatorcontrib><creatorcontrib>Nakao, Shinji</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takami, Akiyoshi</au><au>Ohtake, Shigeki</au><au>Morishita, Eriko</au><au>Terasaki, Yasushi</au><au>Fukushima, Toshihiro</au><au>Kurokawa, Toshiro</au><au>Sugimori, Naomi</au><au>Matano, Sadaya</au><au>Ohata, Kinya</au><au>Saito, Chizuru</au><au>Yamaguchi, Masaki</au><au>Hosokawa, Kohei</au><au>Yamazaki, Hirohito</au><au>Kondo, Yukio</au><au>Nakao, Shinji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>96</volume><issue>3</issue><spage>357</spage><epage>363</epage><pages>357-363</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300 mg per day) due to intolerance, in comparison to optimal-dose imatinib (≥300 mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan–Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420 days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720 days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>22893108</pmid><doi>10.1007/s12185-012-1155-1</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2012-09, Vol.96 (3), p.357-363 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1040997516 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Benzamides Biological and medical sciences Child Female Hematologic and hematopoietic diseases Hematology Humans Imatinib Mesylate Leukemia, Myeloid, Chronic-Phase - drug therapy Leukemia, Myeloid, Chronic-Phase - mortality Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Medicine Medicine & Public Health Middle Aged Oncology Original Article Piperazines - administration & dosage Protein Kinase Inhibitors - administration & dosage Pyrimidines - administration & dosage Retrospective Studies Treatment Outcome Young Adult |
| title | Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A58%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Late%20response%20to%20low-dose%20imatinib%20in%20patients%20with%20chronic%20phase%20chronic%20myeloid%20leukemia&rft.jtitle=International%20journal%20of%20hematology&rft.au=Takami,%20Akiyoshi&rft.date=2012-09-01&rft.volume=96&rft.issue=3&rft.spage=357&rft.epage=363&rft.pages=357-363&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-012-1155-1&rft_dat=%3Cproquest_cross%3E1040997516%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1039599263&rft_id=info:pmid/22893108&rfr_iscdi=true |